Loading…
Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.
Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.
Also sells intraocular lenses, the implants that replace a clouded lens in cataract surgery, to hospitals. Ortho-K lenses are paid for privately by families rather than reimbursed by insurance, and the lenses are replaced as they wear, so sales recur with each child under treatment.
In one line: A Chinese CooperVision/Paragon for myopia-control lenses.
Moat: narrow (regulatory licence, brand). Ortho-K device approvals and clinical fitting expertise limit new entrants.
Headquarters: Beijing, China · Employees: 2,331
Size Eyebright Medical Technology (Beijing) (688050.SS) is a China Health Care company (Medical Specialties) with a market value of $1.27B, the 1885th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥43.71 on 6 Nov 2026.
Performance Over six months the shares fell 14.8%, against -3.3% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 21.1% over the last twelve months (peer median +14.5%); the operating margin is 16.0% (peer median 15.3%).
Valuation It trades at 25.2× forward earnings against a peer median of 30.3× (7th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -29 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (6.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.79B | CN¥1.47B | CN¥1.40B | CN¥944M | CN¥575M |
| Revenue growth | — | +5% | +49% | +64% | — |
| Gross profit | CN¥1.20B | CN¥875M | CN¥871M | CN¥677M | CN¥460M |
| EBITDA | n/a | CN¥533M | CN¥574M | CN¥395M | CN¥284M |
| Net income | CN¥244M | CN¥268M | CN¥388M | CN¥304M | CN¥233M |
| Free cash flow | CN¥146M | CN¥256M | CN¥19.3M | -CN¥144M | CN¥428,190 |
| Capital expenditure | CN¥167M | CN¥123M | CN¥329M | CN¥370M | CN¥271M |
| Total debt | CN¥1.17B | CN¥571M | CN¥579M | CN¥390M | CN¥163M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Eyebright Medical Technology (Beijing) 688050.SS | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% |
| Cooper Companies (The) COO | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% |
| Alcon ALC.SW | $37.5B | +22% | -1% | 11% | 21.4× | 12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688050.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.7% | +0.9% | 3rd highest of 21 |
| 6-month return | -14.8% | -3.3% | 8th lowest of 21 |
| Distance from 52-week high | -38.7% | -34.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +21.1% | +14.5% | 6th highest of 20 |
| Operating margin | 16.0% | 15.3% | 10th highest of 20 |
| Forward P/E | 25.2× | 30.3× | 7th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 10.8% | 9.9% | 5th most demanding of 11 |
| Growth delivered (Del g) | +40.3% | +13.2% | highest of 11 |
| Hurdle (Req g minus delivered) | -29.5 pp | -0.6 pp | 2nd least demanding of 11 |
| ROIC minus cost of capital | +1.4 pp | +0.2 pp | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |